Amgen stock heads into the open after a 2.25% drop
Published on 09/11/2026 at 08:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Amgen stock closed at USD 382.47 on Nasdaq on September 10, 2026, down 2.25% from the prior close as the shares came under fresh pressure. The stock traded between USD 381.51 and USD 391.67 during the session, leaving it well below its 52-week high near USD 447 and closer to the USD 269.77 52-week low, while its drop exceeded the broader market decline that day.
September 10, 2026 in numbers
Amgen Inc. (ISIN US0311621009, Nasdaq: AMGN) saw its September 10, 2026 session defined by a clear pullback, with the Nasdaq close at USD 382.47 after an intraday high of USD 391.67 and a low of USD 381.51, on trading volume of roughly 3.24 million shares per Investing.com data. The move represented a 2.25% decline from the previous Nasdaq close around USD 391.27, positioning the stock below the midpoint of its 52-week range between USD 269.77 and USD 447.03 and marking a notable step down from levels near USD 442 earlier in the month.
Pressure on the shares coincided with a rating change, as Fintel reported that HSBC downgraded Amgen from Buy to Hold on September 10, 2026, while keeping coverage of the name. According to Ad-hoc-news, HSBC also trimmed its price target from USD 445 to USD 425, adding to the cautious tone around the stock and helping explain why Amgen underperformed the major US indices in the latest session. A recap from Yahoo Finance emphasized that Amgen's 2.25% decline on September 10, 2026 was steeper than the broader market's move, underscoring the impact of the downgrade.
Today’s focus for Amgen stock
Looking ahead to today, September 11, 2026, Amgen enters the pre-market without a scheduled earnings release or annual meeting tied directly to this date in the available calendars, but investor attention stays on how the market digests the recent HSBC downgrade and reduced price target. As MarketWatch notes in its coverage of Amgen's valuation and recent trading, the shares now trade below the prior close and somewhat above certain fair-value estimates, which may frame how analysts and investors interpret the rating change through today's session. Broader market sentiment, including moves in the Nasdaq and S&P 500, will also matter for Amgen as a large-cap healthcare constituent, with any further shifts in risk appetite or sector flows likely to influence how the stock trades once the opening bell sounds.
